EC Number   |
Application |
Reference |
|---|
   1.14.11.2 | analysis |
assay method for screening the inhibitors of prolyl 4-hydroxylase to treat fibrosis. The assay uses rat hepatic stellate HSC-6 cells and cobalt chloride as a substitue for a hypoxic condition, the procedure takes three days after treatment with agents |
687351 |
| 1.14.11.2 | diagnostics |
activation of NF-kappaB is observed in colon cancer. PHD3 appears to be a tumor suppressor in colorectal cancer cells that inhibits IKKbeta/NF-kappaB signaling. Determination of PHD3 status could aid targeted therapy selection for patients with colorectal tumors that have increased NF-kappaB activity |
712088 |
| 1.14.11.2 | diagnostics |
the prolyl-4-hydroxylase alpha subunit 2 is a biomarker for breast cancer progression. Increased mRNA levels of P4HA2 correlate with poor clinical outcome in breast cancer patients, which is independent of estrogen receptor status |
744594 |
| 1.14.11.2 | drug development |
P4H is a target for therapeutic drug development in various pathologies, e.g. angiogenesis, fibrosis, ischemia, anemia, and hypoxia, overview |
695593 |
| 1.14.11.2 | drug development |
the enzyme is a target for design of PHD inhibitors aimed at treating anemia and ischemic disease |
701253 |
| 1.14.11.2 | medicine |
enzyme P4Halpha1 overexpression might be a potential therapeutic target in stabilizing vulnerable plaques to prevent rupture and erosion of atherosclerotic plaque and thus thrombosis |
-, 744764 |
| 1.14.11.2 | medicine |
in aortic smooth muscle cell, expression of prolyl-4-hydroxylase is suppressed by tumor necrosis factor TNFalpha via the MKK4-JNK1 pathway, which induces histone 4 lysine 12 acetylation within the TNFalpha response element in the prolyl-4-hydroxylase promoter |
685383 |
| 1.14.11.2 | medicine |
in culture, gingival fibroblasts from Chinese patients with hereditary gingival fibromatosis show similar growth characteristics to fibroblasts isolated from control. mRNA and protein levels of prolyl 4-hydroxylase alpha and type I collagen are higher than those in control. For prolyl 4-hydroxylase alpha(II), prolyl 4-hydroxylase alpha(II) and prolyl 4-hydroxylase beta, no differences between control and hereditary gingival fibromatosis are detected |
684766 |
| 1.14.11.2 | medicine |
P4Halpha1 overexpression might be a valuable therapeutic modality in stabilizing advanced but not early plaque because of the adverse event of accelerated lesion formation |
744826 |
| 1.14.11.2 | medicine |
potential applications of human recombinant collagen, produced by transgenic tobacco expressing the recombinant enzyme, in regenerative medicine |
696584 |
